Mfg News: Bavarian Nordic, Ipsen & NGen

A roundup of manufacturing news from Bavarian Nordic, Ipsen, and NGen. Highlights below.

* Bavarian Nordic, Canada in $470 M Supply Pact for Monkeypox Vaccine
* Ipsen Launches API Mfg Expansion in Ireland
* NGen Invests $10.5 M in Canadian Gov’t Cell-, Gene-Therapy Project

Bavarian Nordic, Canada in $470 M Supply Pact for Monkeypox Vaccine
Bavarian Nordic, a Hellerup (near Copenhagen), Denmark-based vaccine company, and the Public Health Agency of Canada have revised their contract for the supply of Bavarian Nordic’s smallpox and monkeypox vaccine, Imvamune, to now total $470 million. The $470 million includes $56 million previously announced  in June 2022 and an additional $234 million for the supply of the vaccine and $180 million over 10 years in contract options. In addition, the company has signed a new multi-year contract with Canada’s Department of National Defense at a value of $2 million, in addition to $18 million in contract options.

Through the agreements, the majority of the company’s order supply will be delivered in 2023 with the option to procure additional doses annually until 2032.

In addition to smallpox, the vaccine has been approved by the US Food and Drug Administration, Health Canada and the European Commission for use against monkeypox.

Source: Bavarian Nordic

Ipsen Launches API Mfg Expansion in Ireland
Ipsen, a Paris-based bio/pharmaceutical company, has launched an EUR 52 million ($51 million) upgrade to its manufacturing site in Blanchardstown, Ireland (outside of Dublin), which expanded active pharmaceutical ingredient (API) manufacturing. The enhanced site enabled Ipsen to scale its API production at the site by 10% this year (2022) over 2021.

Ipsen plans a further EUR 15 million ($15 million) investment in its Blanchardstown site between 2023 and 2026, which will facilitate continued site enhancement from a technology and sustainability perspective.

Source: IDA Ireland

NGen Invests $10.5 M in Canadian Gov’t Cell-, Gene-Therapy Project
Next Generation Manufacturing Canada (NGen), a not-for-profit organization that leads Canada’s Global Innovation Cluster for Advanced Manufacturing, has announced a $10.5-million contribution to a $34.8-million project that will develop platform technologies for manufacturing cell and gene therapies and train Canada’s workforce in cell- and gene-therapy manufacturing.

The project is being led by OmniaBio, a Hamilton, Ontario, Canada-based CDMO of cell and gene therapies, and has support from partners ExCellThera, a Montreal-based bio/pharmaceutical company, MorphoCell Technologies, a Montreal-based preclinical bio/pharmaceutical company, Aspect Biosystems, a Vancouver-based bio/pharmaceutical company, and the Canadian Advanced Therapies Training Institute (CATTI).

The project consortium, led by OmniaBio, will develop platform technologies that are focused on automated and closed-system manufacturing, quality management systems, analytics and regulatory compliance. ExCellThera, MorphoCell and Aspect Biosystems will advance their respective cell-and gene- therapy (CGT) programs to proceed to commercial production.

Spearheaded by CATTI, the consortium will develop and scale e-learning and onsite cGMP training programs in Quebec and Ontario that will train the Canadian workforce for CGT biomanufacturing.

Source: Next Generation Manufacturing Canada